Takeshi Kato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Takeshi Kato has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Akihiro Sato
Clinical Research Support Office, National Cancer Center Hospital East, Chiba, Japan
1 shared publication- Chan-Young Ock
Lunit, Seoul, Republic of Korea
1 shared publication - Hideaki Bando
Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan
1 shared publication - Ken Kato
Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
1 shared publication - Kentaro Sawada
Department of Medical Oncology, Kushiro Rosai Hospital, Kushiro, Japan
1 shared publication - Mitsuho Imai
Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400385
Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2–Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial
PURPOSE: Human epidermal growth factor receptor 2 (HER2)–targeted therapies have shown promise in treating HER2 -amplified metastatic colorectal cancer (mCRC). Identifying optimal biomarkers for treatment decisions remains challenging. This study explores the potential of artificial intelligence (AI) in predicting treatment responses to trastuzumab plus pertuzumab (TP) in patients with HER2 -amplified mCRC from the phase II TRIUMPH trial. MATERIALS AND METHODS: AI-powered HER2 quantification continuous score (QCS) and tumor microenvironment (TME) analysis were applied to the prescreening cohort (n = 143) and the TRIUMPH cohort (n = 30). AI analyzers determined the proportions of tumor cells (TCs) with HER2 staining intensity and the densities of various cells in TME, examining their associations with clinical outcomes of TP. RESULTS: The AI-powered HER2 QCS for HER2 immunohistochemistry (IHC) achieved an accuracy of 86.7% against pathologist evaluations, with a 100% accuracy for HER2 IHC 3+ patients. Patients with ≥50% of TCs showing HER2 3+ staining intensity (AI-H3-high) exhibited significantly prolonged progression-free survival (PFS; median PFS, 4.4 v 1.4 months; hazard ratio [HR], 0.12 [95% CI, 0.04 to 0.38]) and overall survival (OS; median OS, 16.5 v 4.1 months; HR, 0.13 [95% CI, 0.05 to 0.38]) compared with the AI-H3-low (HER2 -amplified mCRC undergoing TP therapy.
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400385
Open AccessArtificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2–Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial
PURPOSE: Human epidermal growth factor receptor 2 (HER2)–targeted therapies have shown promise in treating HER2 -amplified metastatic colorectal cancer (mCRC). Identifying optimal biomarkers for treatment decisions remains challenging. This study explores the potential of artificial intelligence (AI) in predicting treatment responses to trastuzumab plus pertuzumab (TP) in patients with HER2 -amplified mCRC from the phase II TRIUMPH trial. MATERIALS AND METHODS: AI-powered HER2 quantification continuous score (QCS) and tumor microenvironment (TME) analysis were applied to the prescreening cohort (n = 143) and the TRIUMPH cohort (n = 30). AI analyzers determined the proportions of tumor cells (TCs) with HER2 staining intensity and the densities of various cells in TME, examining their associations with clinical outcomes of TP. RESULTS: The AI-powered HER2 QCS for HER2 immunohistochemistry (IHC) achieved an accuracy of 86.7% against pathologist evaluations, with a 100% accuracy for HER2 IHC 3+ patients. Patients with ≥50% of TCs showing HER2 3+ staining intensity (AI-H3-high) exhibited significantly prolonged progression-free survival (PFS; median PFS, 4.4 v 1.4 months; hazard ratio [HR], 0.12 [95% CI, 0.04 to 0.38]) and overall survival (OS; median OS, 16.5 v 4.1 months; HR, 0.13 [95% CI, 0.05 to 0.38]) compared with the AI-H3-low (HER2 -amplified mCRC undergoing TP therapy.